STAAR Surgical Q3 net sales up 10% to $88.6M; FY China growth outlook halved to 2%

STAAR SURGICAL CO

2024-Q3 EPS reported $0.28 revenue$264,951,000

Net sales $88.6M (+10% YoY); net income $10.0M ($0.20 EPS) vs $4.8M ($0.10) prior year.
Gross margin 77.3% vs 79.2% due to lower production absorption; operating income $5.7M (6.4% of sales).
Adjusted EBITDA $16.2M ($0.33) vs $16.5M ($0.33); maintained FY net sales outlook $340-345M.
China growth outlook cut to ~2% from 10%; APAC 4% (prior 7%), Americas raised to 17% (15%).
Cash $236.0M; management calls China softness transitory, cites potential policy stimulus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.